David A. Scheinberg

David A. Scheinberg is a Professor at Memorial Sloan Kettering Cancer Center, Chair of the Center for Experimental Therapeutics, and Deputy Director of the Sloan Kettering Institute for Therapeutic Discovery. He is affiliated with the Molecular Pharmacology Program, Department of Medicine, and the Tri-Institutional PhD Program in Chemical Biology.

• BA, Cornell University
• MD and PhD, Johns Hopkins University School of Medicine
• Internal Medicine Residency, New York Hospital

Dr. Scheinberg pioneers targeted immunotherapies using antibodies, TCR mimicry, CAR T cells, and nanodevices. His work bridges translational medicine and cancer pharmacology, focusing on intracellular oncogenic proteins like WT1. Key innovations include TCR-like antibodies (2013-2015) and cellular micropharmacies (2021), advancing into clinical trials for leukemia and solid tumors.

His recent publications highlight WT1 as a universal cancer target, bispecific T-cell engagers, and nanoscale drug delivery systems. These studies span

• Antibody-dependent cytotoxicity
• Tumor antigen specificity
• HLA-restricted immune responses
• Nano-machine activation
• Clinical trial translation

Scientific accolades include

• Nature Biotech Top 15 Translational Scientists
• Doris Duke Distinguished Clinical Scientist
• Emil Freireich Prize
• Membership in elite societies: American Association of Physicians, American Society for Clinical Investigation, Interurban Clinical Club

As a mentor, Dr. Scheinberg has advised over 25 graduate students and postdoctoral researchers. His lab collaborates with the Geoffrey Beene Cancer Research Center and Center for Cell Engineering, supported by NIH grants (R01 CA055349, P01 CA023766, UL1 TR000457).